| Issue Date |
Title |
Author(s) |
| 2010 |
Crush Stenting With Drug-Eluting Stents: Relevance of Coronary Bifurcation Lesion Location on Angiographic and Clinical Outcomes |
Chen, Shao-Liang;Zhang, Jun-jie;Ye, Fei;Liu, Zhi-zhong;Zhu, Zhong-sheng;Lin, Song;Tian, Nai-liang;Fang, Wei-yi;Chen, Yun-dai;Sun, Xue-wen;Wei, Meng;Shan, Shou-jie;Kan, Jing;Qian, Jun;Yang, Song;Yuan, Zeng-bai;Kwan, Tak W.;Hu, Da-Yi |
| Apr-2021 |
The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease |
Kim, Hyun Kuk;Tantry, Udaya S.;Smith, Sidney C., Jr.;Jeong, Myung Ho;Park, Seung-Jung;Kim, Moo Hyun;Lim, Do-Sun;Shin, Eun-Seok;Park, Duk-Woo;Huo, Yong;Chen, Shao-Liang;Bo, Zheng;Goto, Shinya;Kimura, Takeshi;Yasuda, Satoshi;Chen, Wen-Jone;Chan, Mark;Aradi, Daniel;Geisler, Tobias;Gorog, Diana A.;Sibbing, Dirk;Lip, Gregory Y. H.;Angiolillo, Dominick J.;Gurbel, Paul A.;Jeong, Young-Hoon |
| 12-Dec-2022 |
Pulmonary Artery Denervation for Pulmonary Arterial Hypertension A Sham-Controlled Randomized PADN-CFDA Trial |
Zhang, Hang;Wei, Yongyue;Zhang, Caojin;Yang, Zhenwen;Kan, Jing;Gu, Heping;Fan, Fenling;Gu, Hong;Wang, Qiguang;Xie, Dujiang;Zhang, Gangcheng;Guo, Xiaomei;Yin, Yuehui;Jin, Bowen;Zhou, Hongmei;Yang, Ziyang;Wang, Zhouming;Xin, Yu;Zhang, Chen;Meng, Lili;Wang, Xiaoyu;Sun, Jingping;Zhao, Chunxia;Zhang, Juan;Yan, Xiaoyan;Chen, Feng;Yao, Cheng;Stone, Gregg W.;Chen, Shao-Liang |
| 2013 |
A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial |
Gao, Run-Lin;Xu, Bo;Lansky, Alexandra J.;Yang, Yue-Jin;Ma, Chang-Sheng;Han, Ya-Ling;Chen, Shao-Liang;Li, Hui;Zhang, Rui-Yan;Fu, Guo-Sheng;Yuan, Zu-Yi;Jiang, Hong;Huo, Yong;Li, Wei;Zhang, Yao-Jun;Leon, Martin B. |
| Oct-2023 |
A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension: one-year outcomes of the PADN-CFDA trial |
Kan, Jing;Zhang, Hang;Xie, Dujiang;Wei, Yongyue;Zhang, Juan;Zhang, Caojin;Yang, Zhenwen;Gu, Heping;Fan, Fenling;Gu, Hong;Wang, Qiguang;Zhang, Gangcheng;Guo, Xiaomei;Yin, Yuehui;Wang, Xiang;Jin, Bowen;Zhou, Hongmei;Yang, Ziyang;Wang, Zhouming;Xin, Yu;Zhang, Chen;Meng, Lili;Wang, Xiaoyu;Zhao, Chunxia;Yan, Xiaoyan;Chen, Feng;Yao, Cheng;Stone, Gregg W.;Chen, Shao-Liang |
| Oct-2023 |
A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension: one-year outcomes of the PADN-CFDA trial |
Kan, Jing;Zhang, Hang;Xie, Dujiang;Wei, Yongyue;Zhang, Juan;Zhang, Caojin;Yang, Zhenwen;Gu, Heping;Fan, Fenling;Gu, Hong;Wang, Qiguang;Zhang, Gangcheng;Guo, Xiaomei;Yin, Yuehui;Wang, Xiang;Jin, Bowen;Zhou, Hongmei;Yang, Ziyang;Wang, Zhouming;Xin, Yu;Zhang, Chen;Meng, Lili;Wang, Xiaoyu;Zhao, Chunxia;Yan, Xiaoyan;Chen, Feng;Yao, Cheng;Stone, Gregg W.;Chen, Shao-Liang |
| Aug-2023 |
Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial |
Zhang, Juan;Kan, Jing;Wei, Yongyue;Zhang, Caojin;Yang, Zhenwen;Gu, Heping;Fan, Fenling;Gu, Hong;Wang, Qiguang;Xie, Dujiang;Zhang, Gangcheng;Guo, Xiaomei;Yin, Yuehui;Jin, Bowen;Zhou, Hongmei;Yang, Ziyang;Wang, Zhouming;Xin, Yu;Zhang, Chen;Meng, Lili;Wang, Xiaoyu;Zhao, Chunxia;Zhang, Hang;Yan, Xiaoyan;Chen, Feng;Yao, Cheng;Benza, Raymond L.;Stone, Gregg W.;Chen, Shao-Liang |
